Email This Release
Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
